{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:59:19Z","timestamp":1773014359382,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jcyt.2019.04.058","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:04:24Z","timestamp":1563235464000},"page":"935-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["T-cell therapies for T-cell lymphoma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-7314","authenticated-orcid":false,"given":"Keri","family":"Toner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcyt.2019.04.058_bib0001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/2040620711408491","article-title":"Evolving therapy of peripheral T-cell lymphoma: 2010 and beyond","volume":"2","author":"Foss","year":"2011","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"10.1016\/j.jcyt.2019.04.058_bib0002","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ajh.24791","article-title":"The aggressive peripheral T-cell lymphomas: 2017","volume":"92","author":"Armitage","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.058_bib0003","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw248","article-title":"T-cell lymphoma: recent advances in characterization and new opportunities for treatment","volume":"109","author":"Casulo","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2019.04.058_bib0004","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/modpathol.2012.177","article-title":"Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course","volume":"26","author":"Swerdlow","year":"2013","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.058_bib0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","article-title":"Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"20","key":"10.1016\/j.jcyt.2019.04.058_bib0006","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-14-2020","article-title":"Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice","volume":"20","author":"O'Connor","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.058_bib0007","first-page":"837","article-title":"Emerging therapies in relapsed and refractory peripheral T-cell lymphoma","volume":"13","author":"Bachow","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.058_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.hoc.2016.11.002","article-title":"Novel agents in the treatment of relapsed or refractory peripheral T-cell lymphoma","volume":"31","author":"Marchi","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.058_bib0009","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13045-017-0518-8","article-title":"Erratum to: romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"10","author":"Foss","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2019.04.058_bib0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11899-018-0480-8","article-title":"Novel immunotherapies for T cell lymphoma and leukemia","volume":"13","author":"Ghione","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.058_bib0011","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Coiffier","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"24","key":"10.1016\/j.jcyt.2019.04.058_bib0012","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood-2018-01-785840","article-title":"Chimeric antigen receptor-modified T cells: CD19 and the road beyond","volume":"131","author":"Salter","year":"2018","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jcyt.2019.04.058_bib0013","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1001\/jama.2017.15605","article-title":"The Promise and Challenges of CAR-T Gene Therapy","volume":"318","author":"Kuehn","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jcyt.2019.04.058_bib0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T Cell Therapy for Lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.058_bib0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12126","article-title":"CAR T cells: driving the road from the laboratory to the clinic","volume":"257","author":"Cheadle","year":"2014","journal-title":"Immunol Rev"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.058_bib0016","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.058_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.jcyt.2019.04.058_bib0018","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.6004\/jnccn.2017.7045","article-title":"Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma","volume":"15","author":"Avanzi","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"10.1016\/j.jcyt.2019.04.058_bib0019","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/bloodadvances.2017009886","article-title":"Developing T-cell therapies for lymphoma without receptor engineering","volume":"1","author":"Grant","year":"2017","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.jcyt.2019.04.058_bib0020","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1158\/1078-0432.CCR-11-1873","article-title":"Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4","volume":"17","author":"Cruz","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.058_bib0021","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/asheducation-2014.1.565","article-title":"Cytotoxic T lymphocytes for leukemia and lymphoma","volume":"2014","author":"Bollard","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.058_bib0022","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.058_bib0023","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.058_bib0024","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2019.04.058_bib0025","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"issue":"68","key":"10.1016\/j.jcyt.2019.04.058_bib0026","doi-asserted-by":"crossref","first-page":"112783","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.058_bib0027","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2019.04.058_bib0028","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-6655-4_19","article-title":"EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas","volume":"1532","author":"McLaughlin","year":"2017","journal-title":"Methods Mol Biol"},{"issue":"22","key":"10.1016\/j.jcyt.2019.04.058_bib0029","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.058_bib0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.blre.2017.11.004","article-title":"Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!","volume":"32","author":"Grant","year":"2018","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.058_bib0031","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2007-05-091280","article-title":"Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer","volume":"110","author":"Bollard","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.058_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2019.04.058_bib0033","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10428190802311417","article-title":"Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas","volume":"49","author":"Cohen","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.058_bib0034","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/08880018.2011.628367","article-title":"T-cell therapies for Epstein-Barr virus-associated lymphomas","volume":"28","author":"El-Bietar","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.058_bib0035","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/mt.2011.167","article-title":"Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma","volume":"19","author":"Gerdemann","year":"2011","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.jcyt.2019.04.058_bib0036","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.4049\/jimmunol.1501657","article-title":"Landscape of Tumor Antigens in T Cell Immunotherapy","volume":"195","author":"Ilyas","year":"2015","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.058_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090339","article-title":"Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas","volume":"10","author":"Poggio","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.058_bib0038","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.058_bib0039","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CCO.0000000000000469","article-title":"New perspectives in the therapeutic approach of peripheral T-cell lymphoma","volume":"30","author":"Gisselbrecht","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.058_bib0040","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17474086.2016.1205949","article-title":"New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma","volume":"9","author":"Merli","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.058_bib0041","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","article-title":"Diagnostic, prognostic and therapeutic role of CD30 in lymphoma","volume":"10","author":"Pierce","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.058_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040099","article-title":"Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond","volume":"10","author":"Prokoph","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.058_bib0043","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.058_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020317","article-title":"Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy","volume":"20","author":"Zhang","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.058_bib0045","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.jcyt.2019.04.058_bib0046","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Scarfo","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2019.04.058_bib0047","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000431059","article-title":"Clinical Application of Anti-CCR4 Monoclonal Antibody","volume":"89","author":"Ueda","year":"2015","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.058_bib0048","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14712598.2017.1347634","article-title":"Mogamulizumab for the treatment of T-cell lymphoma","volume":"17","author":"Makita","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.058_bib0049","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.jcyt.2019.04.058_bib0050","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci"},{"issue":"7","key":"10.1016\/j.jcyt.2019.04.058_bib0051","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.058_bib0052","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2019.04.058_bib0053","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-Oncology: Emerging Targets and Combination Therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.058_bib0054","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The Next Immune-Checkpoint Inhibitors: PD-1\/PD-L1 Blockade in Melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcyt.2019.04.058_bib0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.058_bib0056","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.3802\/jgo.2017.28.e64","article-title":"Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer","volume":"28","author":"Zhu","year":"2017","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.058_bib0057","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2217\/epi.15.16","article-title":"Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy","volume":"7","author":"Park","year":"2015","journal-title":"Epigenomics"},{"issue":"6","key":"10.1016\/j.jcyt.2019.04.058_bib0058","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","article-title":"Targeting histone deacetylases in T-cell lymphoma","volume":"58","author":"Moskowitz","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.058_bib0059","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-15-1435","article-title":"Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL","volume":"22","author":"Rozati","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.058_bib0060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919307479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324919307479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:40:10Z","timestamp":1761442810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324919307479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1465324919307479"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.04.058","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell therapies for T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.04.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}